Therapeutic Asset Ratings
766 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
[225Ac]-FPI-1966
Urinary Bladder Carcinoma
Fusion Pharmaceuticals Inc.
P1/2
CC
(47)
Yttrium-90
Macrovascular Invasion
University Health Network, Toronto
P1/2
CC
(47)
177lu-p17-088
Prostate Cancer
First Affiliated Hospital of Fujian Medical University
P2
CC
(46)
177Lu-PSMA-I&T
Prostate Cancer
Medical University of Vienna
P2
CC
(46)
68ga-hbed-ipsma
Prostate Cancer
Memorial Sloan Kettering Cancer Center
P2
CC
(46)
68GaNOTA-Anti-HER2 VHH1
Breast Cancer
Centre Henri Becquerel
P2
CC
(46)
Fluciclovine
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
Yttrium-90-Labeled Fibroblast Activation Protein Inhibitor
Non-Small Cell Lung Carcinoma
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
P2
CC
(46)
177lu-dansyl-psma radioligand therapy
Castration-Resistant Prostate Carcinoma
The First Affiliated Hospital of Xiamen University
P1
CC
(46)
[68ga]ga-oncoacp3
Metastatic Prostate Carcinoma
Philogen S.p.A.
P1
CC
(46)
[68ga]ga-oncofap administration
Pancreatic Adenocarcinoma
Philogen S.p.A.
P1
CC
(46)
Gallium-68 Labelled Fap-2286
Fibrotic Liver Disease
Thomas Hope
P1
CC
(46)
Gallium-68 Labelled Fap-2286
Pulmonary Fibrosis
Thomas Hope
P1
CC
(46)
161tb rad402
Castration-Resistant Prostate Carcinoma
Radiopharm Theranostics, Ltd
P1/2
CC
(45)
177lu-betabart
Non-Small Cell Lung Carcinoma
Radiopharm Theranostics, Ltd
P1/2
CC
(45)
[177lu]lu-dpi-4452
Urothelial Carcinoma
ITM Oncologics GmbH
P1/2
CC
(45)
[177lu]lu-sn201
Locally Advanced Solid Tumor
Spago Nanomedical AB
P1/2
CC
(45)
[203pb]pb-psv359
Mesothelioma
Perspective Therapeutics
P1/2
CC
(45)
[212pb]pb-mp0712
Small Cell Lung Carcinoma
Molecular Partners AG
P1/2
CC
(45)
[212pb]pb-psv359
Mesothelioma
Perspective Therapeutics
P1/2
CC
(45)
64cu-grip b
Renal Cell Carcinoma
Rahul Aggarwal
P1/2
CC
(45)
67cu-sar-bispsma
Castration-Resistant Prostate Carcinoma
Clarity Pharmaceuticals Ltd
P1/2
CC
(45)
68ga-g21
Prostate Adenocarcinoma
First Affiliated Hospital of Fujian Medical University
P1/2
CC
(45)
68ga-g23
Prostate Adenocarcinoma
First Affiliated Hospital of Fujian Medical University
P1/2
CC
(45)
68ga-p15-041
Metastatic Prostate Carcinoma
Peking Union Medical College Hospital
P1/2
CC
(45)
Showing 201 to 225 of 766 assets
Previous
Page 9 of 31
Next
